| 112.8 -1.66 (-1.45%) | 07-08 11:41 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 134.74 |
1-year : | 157.37 |
| Resists | First : | 115.36 |
Second : | 134.74 |
| Pivot price | 105.13 |
|||
| Supports | First : | 95.29 |
Second : | 82.88 |
| MAs | MA(5) : | 112.34 |
MA(20) : | 100.62 |
| MA(100) : | 91.71 |
MA(250) : | 97.55 |
|
| MACD | MACD : | 6.4 |
Signal : | 5.2 |
| %K %D | K(14,3) : | 94.8 |
D(3) : | 92.7 |
| RSI | RSI(14): 75.1 |
|||
| 52-week | High : | 122.19 | Low : | 74.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RYTM ] has closed below upper band by 21.2%. Bollinger Bands are 111.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 115.47 - 116.03 | 116.03 - 116.51 |
| Low: | 109.82 - 110.46 | 110.46 - 111.01 |
| Close: | 113.49 - 114.49 | 114.49 - 115.36 |
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Mon, 06 Jul 2026
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Contender with 22% Upside Potential - DirectorsTalk Interviews
Sun, 05 Jul 2026
Price to sales forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM - TradingView
Sat, 04 Jul 2026
RYTM - Rhythm Pharmaceuticals Inc Options - Finviz
Fri, 03 Jul 2026
Rhythm Pharmaceuticals Inc to Discuss Interim Six-Month Phase 2 Results Evaluating Setmelanotide Call Transcript - GuruFocus
Fri, 03 Jul 2026
RYTM - Rhythm Pharmaceuticals Inc Latest SEC Filings - Finviz
Thu, 02 Jul 2026
Rhythm Pharmaceuticals (RYTM) CSO exercises RSUs, 2,150 shares withheld for taxes - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 69 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 109.9 (%) |
| Shares Short | 8,010 (K) |
| Shares Short P.Month | 8,280 (K) |
| EPS | -3.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.79 |
| Profit Margin | -93.4 % |
| Operating Margin | -87.2 % |
| Return on Assets (ttm) | -29.8 % |
| Return on Equity (ttm) | -101.2 % |
| Qtrly Rev. Growth | 83.8 % |
| Gross Profit (p.s.) | 2.83 |
| Sales Per Share | 3.16 |
| EBITDA (p.s.) | -2.87 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -120 (M) |
| Levered Free Cash Flow | -151 (M) |
| PE Ratio | -36.57 |
| PEG Ratio | 0 |
| Price to Book value | 63.58 |
| Price to Sales | 36.15 |
| Price to Cash Flow | -65.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|